Related references
Note: Only part of the references are listed.Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD
Paolo Montuschi et al.
FRONTIERS IN PHARMACOLOGY (2018)
The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD
Mitsuhiro Yamada et al.
FRONTIERS IN PHARMACOLOGY (2018)
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects
Mario Malerba et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease
Mario Malerba et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
Michele R. Wilson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2017)
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
Kesavan Suresh Babu et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2017)
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study
Gregory J. Feldman et al.
ADVANCES IN THERAPY (2017)
Triple inhaled therapy for chronic obstructive pulmonary disease
Paolo Montuschi et al.
DRUG DISCOVERY TODAY (2016)
Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis
Roy A. Pleasants et al.
DRUGS (2016)
Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
Chris Kalberg et al.
DRUGS IN R&D (2016)
Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
Marc Miravitlles et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD
Gregory Feldman et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
Vilanterol trifenatate for the treatment of COPD
Mario Malerba et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2016)
UK-specific cost-effectiveness of tiotropium
Abigail Tebboth et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2016)
Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers
Giuseppe Santini et al.
JOURNAL OF BREATH RESEARCH (2016)
Role of beta-blockers in patients with COPD: current perspective
Mario Malerba et al.
DRUG DISCOVERY TODAY (2015)
Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends
Paolo Montuschi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Umeclidinium-vilanterol inhaler approved for COPD
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2014)
Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD A Randomized, Controlled Study
Bartolome Celli et al.
CHEST (2014)
Pharmacological treatment of chronic obstructive pulmonary disesse: from evidence-based medicine to phenotyping
Paolo Montuschi et al.
DRUG DISCOVERY TODAY (2014)
Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Roopa Trivedi et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
M. Reza Maleki-Yazdi et al.
RESPIRATORY MEDICINE (2014)
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Marc Decramer et al.
LANCET RESPIRATORY MEDICINE (2014)
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study
James F. Donohue et al.
RESPIRATORY RESEARCH (2014)
Inhaled Muscarinic Acetylcholine Receptor Antagonists for Treatment of COPD
P. Montuschi et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD
L. Fuso et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
J. F. Donohue et al.
RESPIRATORY MEDICINE (2013)
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
Donald P. Tashkin et al.
RESPIRATORY RESEARCH (2013)
In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting beta(2)-Adrenoceptor Agonist with 24-Hour Duration of Action
Robert J. Slack et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases
Michael Salmon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Symptom variability in patients with severe COPD: a pan-European cross-sectional study
R. Kessler et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease A Randomized Crossover Trial
Andrew Jabbour et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
The salmeterol multicenter asthma research trial - A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
HS Nelson et al.
CHEST (2006)
Current concepts - Management of chronic obstructive pulmonary disease
ER Sutherland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
